Table 2. Incidence of TB according to bDMARDs and stratified before and after 2012.
| Total | Event (%) | Total person-years | Incidence Rate (/105 years) | IRR (95% CI) † | |
|---|---|---|---|---|---|
| 2000–2011 | |||||
| ETN | 335 | 10 (3.0) | 1286.4 | 777.4 | 1 |
| ADA | 236 | 9 (3.8) | 906.0 | 993.4 | 1.35 (0.73–2.48)* |
| GLN | - | - | - | - | - |
| TCZ | - | - | - | - | - |
| ABA | - | - | - | - | - |
| TOF | - | - | - | - | - |
| Total | 571 | 19(3.3) | 2192.4 | 866.6 | - |
| 2012–2015 | |||||
| ETN | 108 | 3 (2.8) | 175.4 | 1710.6 | 1 |
| ADA | 96 | 2(2.1) | 136.1 | 1469.1 | 1.09 (0.55–2.19)# |
| GLN | 60 | 0 (0.0) | 94 | 0.0 | - |
| TCZ | 31 | 0 (0.0) | 55.49 | 0.0 | - |
| ABA | 74 | 0 (0.0) | 105.3 | 0.0 | - |
| TOF | 11 | 0 (0.0) | 1.91 | 0.0 | - |
| Total | 380 | 5(1.3) | 568.2 | 879.9 | - |
| 2000–2015 | |||||
| ETN | 443 | 13 (2.9) | 1461.8 | 889.3 | 1 |
| ADA | 332 | 11 (3.3) | 1042.1 | 1055.6 | 1.27 (0.76–2.13)& |
| GLN | 60 | 0 (0.0) | 94.0 | 0 | - |
| TCZ | 31 | 0 (0.0) | 55.5 | 0 | - |
| ABA | 74 | 0 (0.0) | 105.3 | 0 | - |
| TOF | 11 | 0 (0.0) | 1.9 | 0 | - |
| Total | 951 | 24(2.5) | 2758.7 | 870.0 | - |
†Adjusted for sex and age;
*p = 0.334;
#p = 0.803;
&p = 0.556 by Poisson model
Abbreviations: TB, tuberculosis; bDMARDs, biological drug modifying anti-rheumatic drugs; tDMARDs, targeted disease modifying anti-rheumatic drugs; ETN, etanercept; ADA, adalimumab; GLN, golimumab; TCZ, tocilizumab; ABA, abatacept; TOF, tofacitinib; IRR, incidence rate ratio.